AbCellera Biologics (ABCL) said Monday that the US Court of Appeals for the Federal Circuit has affirmed judgment of validity of its US patent 10,087,408, which is directed to microfluidic devices used for culturing and selectively recovering cells.
The patent was challenged by Bruker Cellular Analysis, a subsidiary of Bruker (BRKR), which alleged invalidity based on "anticipation and obviousness over the prior art," the company said. However, Bruker's arguments were rejected by the US Patent Trial and Appeal Board.
AbCellera's patent is part of a multi-patent infringement litigation between AbCellera and Bruker pending in the US District Court for the Northern District of California.
Bruker didn't immediately respond to a request for comment from MT Newswires.
Price: 2.07, Change: +0.04, Percent Change: +1.72
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。